# Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

> **NCT00987480** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Aplastic Anemia
- Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.
- **DEVICE:** CliniMACS device

## Key facts

- **NCT ID:** NCT00987480
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-25
- **Primary completion:** 2017-07-10
- **Final completion:** 2017-07-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00987480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00987480, "Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00987480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*